JP2016511277A5 - - Google Patents

Download PDF

Info

Publication number
JP2016511277A5
JP2016511277A5 JP2015562182A JP2015562182A JP2016511277A5 JP 2016511277 A5 JP2016511277 A5 JP 2016511277A5 JP 2015562182 A JP2015562182 A JP 2015562182A JP 2015562182 A JP2015562182 A JP 2015562182A JP 2016511277 A5 JP2016511277 A5 JP 2016511277A5
Authority
JP
Japan
Prior art keywords
seq
cdr
represented
region
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511277A (ja
JP6543197B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055066 external-priority patent/WO2014140248A1/en
Publication of JP2016511277A publication Critical patent/JP2016511277A/ja
Publication of JP2016511277A5 publication Critical patent/JP2016511277A5/ja
Application granted granted Critical
Publication of JP6543197B2 publication Critical patent/JP6543197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562182A 2013-03-15 2014-03-14 Bcmaおよびcd3に対する結合分子 Active JP6543197B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793235P 2013-03-15 2013-03-15
US61/793,235 2013-03-15
PCT/EP2014/055066 WO2014140248A1 (en) 2013-03-15 2014-03-14 Binding molecules for bcma and cd3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019042216A Division JP2019129830A (ja) 2013-03-15 2019-03-08 Bcmaおよびcd3に対する結合分子

Publications (3)

Publication Number Publication Date
JP2016511277A JP2016511277A (ja) 2016-04-14
JP2016511277A5 true JP2016511277A5 (enExample) 2017-04-13
JP6543197B2 JP6543197B2 (ja) 2019-07-17

Family

ID=50473264

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015562182A Active JP6543197B2 (ja) 2013-03-15 2014-03-14 Bcmaおよびcd3に対する結合分子
JP2019042216A Pending JP2019129830A (ja) 2013-03-15 2019-03-08 Bcmaおよびcd3に対する結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019042216A Pending JP2019129830A (ja) 2013-03-15 2019-03-08 Bcmaおよびcd3に対する結合分子

Country Status (22)

Country Link
US (1) US10752694B2 (enExample)
EP (2) EP3912997A3 (enExample)
JP (2) JP6543197B2 (enExample)
KR (1) KR20150130412A (enExample)
CN (2) CN111484556A (enExample)
AR (1) AR095374A1 (enExample)
AU (2) AU2014230217B2 (enExample)
BR (1) BR112015020277A2 (enExample)
CA (1) CA2899830C (enExample)
CL (1) CL2015002742A1 (enExample)
EA (1) EA201591692A1 (enExample)
HK (1) HK1223629A1 (enExample)
IL (1) IL241332A0 (enExample)
MX (1) MX372679B (enExample)
PE (1) PE20151920A1 (enExample)
PH (1) PH12015501672A1 (enExample)
SG (1) SG11201506184WA (enExample)
TW (1) TWI646107B (enExample)
UA (1) UA118757C2 (enExample)
UY (1) UY35456A (enExample)
WO (1) WO2014140248A1 (enExample)
ZA (1) ZA201505209B (enExample)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0919840B1 (pt) * 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
WO2014122144A1 (en) * 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
TN2017000275A1 (en) 2015-01-23 2018-10-19 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
ES2905315T3 (es) 2015-04-13 2022-04-07 Pfizer Anticuerpos terapéuticos y sus usos
KR102528825B1 (ko) * 2015-04-13 2023-05-08 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
JP2018515123A (ja) 2015-05-18 2018-06-14 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Msln及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Egfrviii及cd3抗體構築體
WO2017021450A1 (en) 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
CA3004900C (en) 2015-11-18 2021-08-10 Merck Sharp & Dohme Corp. Ctla4 binders
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
KR102688969B1 (ko) 2016-02-03 2024-07-30 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
IL260732B2 (en) 2016-02-17 2024-08-01 Seagen Inc Bcma antibodies and use of same to treat cancer and immunological disorders
EP3423482A1 (en) 2016-03-04 2019-01-09 Novartis AG Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
PL3443096T3 (pl) 2016-04-15 2023-06-19 Novartis Ag Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych
RU2019105693A (ru) 2016-08-01 2020-09-01 Новартис Аг Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
AU2018228719B2 (en) 2017-02-28 2023-03-30 Affimed Gmbh Tandem diabody for CD16A-directed NK-cell engagement
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
JP2020533383A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 癌の組合せ治療
BR112020005028A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento em combinação para câncer
PE20201183A1 (es) * 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
RU2020119365A (ru) 2017-11-15 2021-12-13 Новартис Аг Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
BR112020012554A2 (pt) 2017-12-22 2020-11-24 Teneobio, Inc. anticorpos de cadeia pesada que se ligam a cd22
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
CN112272675A (zh) * 2018-02-21 2021-01-26 细胞基因公司 Bcma结合抗体及其用途
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112119097B (zh) 2018-04-13 2021-10-15 艾菲默德有限责任公司 自然杀伤细胞接合抗体融合构建体
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
EP3808376A4 (en) 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. TARGET ANTIBODIES CLDN18.2, BISPECIFIC ANTIBODIES, ADC AND CAR, AND THEIR APPLICATIONS
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
SMT202500371T1 (it) 2018-07-19 2025-11-10 Regeneron Pharma Recettori chimerici dell’antigene con specificità per bcma e loro usi
AU2019316164A1 (en) * 2018-07-31 2021-01-21 Amgen Inc. Dosing regimen for BCMA-CD3 bispecific antibodies
AU2019318083A1 (en) * 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
TW202538050A (zh) 2018-08-31 2025-10-01 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CN112703204B (zh) * 2018-09-28 2024-10-01 安进公司 针对可溶性bcma的抗体
JP2022509454A (ja) 2018-10-31 2022-01-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の処置法
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020146431A1 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Improved targeted t-cell therapy for treatment of multiple myeloma
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CA3126087A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
CN120775051A (zh) 2019-05-21 2025-10-14 诺华股份有限公司 Cd19结合分子及其用途
EA202290054A1 (ru) 2019-06-14 2022-03-25 Тенеобио, Инк. Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CN114502593A (zh) 2019-08-06 2022-05-13 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和相关方法
US12479922B2 (en) 2019-10-10 2025-11-25 Cytolynx Therapeutics Hong Kong Limited Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
US11919965B2 (en) 2019-12-06 2024-03-05 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
TW202146441A (zh) 2020-02-27 2021-12-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子,其製備方法及醫藥用途
CA3182697A1 (en) * 2020-05-11 2021-11-18 Janssen Biotech, Inc. Methods for treating multiple myeloma
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
CN117396513A (zh) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的联合疗法
KR20240040786A (ko) 2021-08-03 2024-03-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
US20250000973A1 (en) 2021-08-20 2025-01-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN118159294A (zh) 2021-10-05 2024-06-07 葛兰素史密斯克莱知识产权发展有限公司 用于治疗癌症的联合疗法
JP2024540054A (ja) 2021-11-03 2024-10-31 ヤンセン バイオテツク,インコーポレーテツド 癌を治療する方法及びbcma×cd3二重特異性抗体の有効性を向上させる方法
EP4469484A1 (en) 2022-01-25 2024-12-04 GlaxoSmithKline Intellectual Property Development Ltd Combination therapy for cancer
KR20250004700A (ko) 2022-04-11 2025-01-08 리제너론 파마슈티칼스 인코포레이티드 보편적 종양 세포 사멸을 위한 조성물 및 방법
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
EP4630454A1 (en) 2022-12-05 2025-10-15 GlaxoSmithKline Intellectual Property Development Ltd Methods of treatment using b-cell maturation antigen antagonists
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202502811A (zh) * 2023-06-01 2025-01-16 瑞士商赫孚孟拉羅股份公司 與bcma特異性結合之免疫刺激性抗原結合分子
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) 1841-03-12 Improvement in horizontal windivhlls
US70185A (en) 1867-10-29 fan oh be
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
EP2366718A3 (en) * 2002-06-28 2012-05-02 Domantis Limited Ligand
EP1629013B1 (en) 2003-05-31 2018-01-24 Amgen Research (Munich) GmbH Pharmaceutical composition comprising a bispecific antibody specific for epcam
EP1709072A1 (en) 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP3461842A1 (en) 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
AU2009239437B2 (en) * 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
HUE029619T4 (en) * 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2012066058A1 (en) * 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
CA2833820C (en) * 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN118994397A (zh) * 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途

Similar Documents

Publication Publication Date Title
JP2016511277A5 (enExample)
JP2014534242A5 (enExample)
JP2015504306A5 (enExample)
US11512129B2 (en) TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
JP6480907B2 (ja) 多量体化技術
JP2022037133A (ja) 改良された血清アルブミン結合剤
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN113817066A (zh) 自然杀伤细胞接合抗体融合构建体
JP2016512551A5 (enExample)
AU2016370659A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
JP2020506898A5 (enExample)
JP7257971B2 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
CN110536900A (zh) 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
JP2017522903A5 (enExample)
CN114470193A (zh) 对人类cd19具有专一性的抗体药剂和其用途
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
JP2010524435A5 (enExample)
US20220306760A1 (en) Igm glycovariants
EA039946B1 (ru) Антитела-антагонисты к интерферону альфа и интерферону омега
JP2016040322A (ja) 改変抗体及びその作製方法
CA3111462A1 (en) Improved anti-flt3 antigen binding proteins
CN109721656B (zh) 靶向rankl的治疗性抗体
KR20240049621A (ko) 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자